Drug Profile
Glipizide/metformin - Bristol-Myers Squibb
Alternative Names: Metaglip; metformin/glipizideLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics; Biguanides; Small molecules; Sulfonylureas
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 03 Jul 2019 Chemical structure information added
- 19 Jun 2003 Launched for Type-2 diabetes mellitus in USA (PO)